Even though the exact cause of pulmonary arterial hypertension (PAH) is still unknown and there is no cure, the last decade has seen significant advances in the understanding of the pathophysiology of PAH, transforming the prognosis for PAH patients from symptomatic improvements in exercise tolerance 10 years ago, to delayed disease progression today.1-4
Explore these developments and more in PAH Perspectives, which features clinical perspective and data to inform healthcare professionals caring for PAH patients.
©2022 Actelion Pharmaceuticals US, Inc. All rights reserved. cp-139253v5 04/22
1. Pulmonary Arterial Hypertension. National Association of Rare Disorders. Updated 2021. Accessed September 21, 2021. https://raredisease.org/rare-diseases/pulmonary-arterial-hypertension/
2. McLaughlin V. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 2011 20: 262-269.
3. Vachiéry J and Gaine G. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev 2012;21(126):313-20.
4. Rosanio S, Pelliccia F, Gaudio C, et al. Pulmonary arterial hypertension in adults: Novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies. BioMed Research International 2014: 743868.
